Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Stomach cancer, though not as common as some other forms of cancer, can be a serious and life-threatening condition if not ...

Rare gastrointestinal lesions are seldom seen in endoscopy, limiting data for AI and clinician training. Here, authors present EndoRare, a one-shot retraining-free framework that synthesizes diverse ...

Shares of ArriVent BioPharma rose after the company announced positive initial data from a Phase 1 trial of treatment for gastrointestinal cancers. The stock gained 9.3% to $22.95 in premarket trading ...

A breakthrough treatment has made significant progress, showing promising results in decreasing recurrence and death from a ...

FDA approves Tukysa maintenance therapy with Herceptin and Perjeta, extending progression-free survival by over eight months ...

AstraZeneca ( AZN) said its experimental stomach cancer treatment doubled survival time in a late-stage clinical trial, ...

Two Phase 3 trials presented at Europe's leading oncology conference show major survival gains: Roche's divarasib outperforms ...

Global Fabry Disease Market size is expected to be worth around US$ 5.3 Billion by 2034 from US$ 2.5 Billion in 2024.

Gastrointestinal diseases are those that affect any section of the gastrointestinal tract, from the oesophagus to the rectum, and the accessory digestive organs – liver, gall bladder and pancreas. The ...

"Doctor, I've been taking this stomach medicine for about 10 years now. Is that okay?"I am often asked this during outpatient ...

GLP-1 receptor agonists support weight loss and metabolic control in people with inflammatory bowel disease, while ...